Physicians' Education Resource®, LLC, (PER®) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by educational grants from Eisai, Inc., and Exelixis, Inc.
Release Date: August 30, 2018
Expiration Date: August 30, 2019
Media: Internet - based
Instructions for This Activity and Receiving Credit
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with hepatocellular carcinoma (HCC). Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with HCC also are invited to participate.
At the conclusion of this activity, participants should be better prepared to:
Alan P. Venook, MD, FASCO
Madden Family Distinguished Professor in Medical Oncology and Translational Research
Shorenstein Associate Director, Program Development
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, CA
Disclosure: Grant/Research Support: Genentech, Roche; Consultant: Halozyme
Anthony El-Khoueiry, MD
Associate Professor of Clinical Medicine
Norris Cancer Center CISO Chair
Keck School of Medicine
University of Southern California
Los Angeles, CA
Disclosure: Dr. El-Khoueiry reports no relevant financial relationships with commercial interests to disclose.
Jordi Bruix, MD, PhD
Professor of Medicine
University of Barcelona
Director, Barcelona Clinic Liver Cancer (BCLC) Group
Liver Unit at the Hospital Clinic
Disclosure: Grant/Research Support: Bayer; Consultant: Daiichi Sankyo, ArQule, Bayer, AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, Kowa, Novartis, Roche, Onxeo, Terumo, Sirtex; Advisory Boards: Bayer, AbbVie, Bristol-Myers Squibb, Novartis, Roche, Onxeo, Terumo, Sirtex, BTG
Ghassan K. Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: Agios, Array, AstraZeneca, Bayer, BMS, Casi, Celgene, Exelixis, Genentech, Incyte, Lilly, MabVax, MedImmune, Momenta, Novartis, OncoMed Pharmaceuticals, Roche; Consultant: Agios, Amgen, Antengene, Aptus, Aslan, Astellas, AstraZeneca, Bayer, BMS, Boston Scientific, CARsgen, Celgene, Casi, CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Gilead, Halozyme, Inovio, Ipsen, Merck, Onxeo, PCI Biotech, Roche, Sanofi, Servier, Silenseed, Sillajen, Sirtex, Yakult
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
March 7, 2019 - March 10, 2019
March 8, 2019
Cancer Summaries and Commentaries™: Update from Atlanta – Advances in the Treatment of Acute Myeloid Leukemia
Mar 30, 2019
Mar 30, 2019
Mar 30, 2019